Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan

current trends and issues

M. Harada, Katsuto Takenaka, S. Nakao, N. Aotsuka, H. Sawada, K. Shinagawa, M. Kasai, T. Iseki, M. Murata, S. Okamoto, H. Hyodo, Y. Kodera

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In December 1997, we conducted a nationwide survey of cases of primary allogeneic peripheral blood stem cell transplantation (allo-PBSCT) performed in Japan between December 1994 and November 1997 Data was collected on 103 patients with hematologic malignancies, aplastic anemia, or solid tumors. Eighty-seven patients received transplants from HLA-identical siblings, and 16 from HLA-mismatched related donors. Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) were collected from donors by 1 to 3 aphereses. Apheresis products contained a median 5.4 (1.0-30.4) x 10(6) CD34 + cells/kg. Most patients were given cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Median days to ANC > 500/microliter and platelets > 50,000/microliter were 13 (7-49) and 16 (10-94), respectively. Grade II-IV acute GVHD developed in 37/99 (37.4%) and chronic GVHD in 59/86 (68.6%) patients. The incidence of treatment-related mortality within 100 days after transplant was 16.1%. Fifty-five patients (59.6%) were alive after a median follow-up of 794 days. More patients and longer follow-up periods will be required to assess the efficacy of allo-PBSCT and evaluate graft-versus-leukemia effect along with the incidence of acute and chronic GVHD.

Original languageEnglish
Pages (from-to)1160-1167
Number of pages8
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume40
Issue number11
Publication statusPublished - Jan 1 1999

Fingerprint

Peripheral Blood Stem Cell Transplantation
Japan
Tissue Donors
Graft vs Host Disease
Blood Component Removal
Transplants
Aplastic Anemia
Incidence
Granulocyte Colony-Stimulating Factor
Hematologic Neoplasms
Methotrexate
Cyclosporine
Surveys and Questionnaires
Siblings
Leukemia
Blood Platelets
Mortality
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan : current trends and issues. / Harada, M.; Takenaka, Katsuto; Nakao, S.; Aotsuka, N.; Sawada, H.; Shinagawa, K.; Kasai, M.; Iseki, T.; Murata, M.; Okamoto, S.; Hyodo, H.; Kodera, Y.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 40, No. 11, 01.01.1999, p. 1160-1167.

Research output: Contribution to journalArticle

Harada, M, Takenaka, K, Nakao, S, Aotsuka, N, Sawada, H, Shinagawa, K, Kasai, M, Iseki, T, Murata, M, Okamoto, S, Hyodo, H & Kodera, Y 1999, 'Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan: current trends and issues', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 40, no. 11, pp. 1160-1167.
Harada, M. ; Takenaka, Katsuto ; Nakao, S. ; Aotsuka, N. ; Sawada, H. ; Shinagawa, K. ; Kasai, M. ; Iseki, T. ; Murata, M. ; Okamoto, S. ; Hyodo, H. ; Kodera, Y. / Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan : current trends and issues. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 1999 ; Vol. 40, No. 11. pp. 1160-1167.
@article{3fe0ca9393be4fe3930b6bb2cf05a86e,
title = "Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan: current trends and issues",
abstract = "In December 1997, we conducted a nationwide survey of cases of primary allogeneic peripheral blood stem cell transplantation (allo-PBSCT) performed in Japan between December 1994 and November 1997 Data was collected on 103 patients with hematologic malignancies, aplastic anemia, or solid tumors. Eighty-seven patients received transplants from HLA-identical siblings, and 16 from HLA-mismatched related donors. Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) were collected from donors by 1 to 3 aphereses. Apheresis products contained a median 5.4 (1.0-30.4) x 10(6) CD34 + cells/kg. Most patients were given cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Median days to ANC > 500/microliter and platelets > 50,000/microliter were 13 (7-49) and 16 (10-94), respectively. Grade II-IV acute GVHD developed in 37/99 (37.4{\%}) and chronic GVHD in 59/86 (68.6{\%}) patients. The incidence of treatment-related mortality within 100 days after transplant was 16.1{\%}. Fifty-five patients (59.6{\%}) were alive after a median follow-up of 794 days. More patients and longer follow-up periods will be required to assess the efficacy of allo-PBSCT and evaluate graft-versus-leukemia effect along with the incidence of acute and chronic GVHD.",
author = "M. Harada and Katsuto Takenaka and S. Nakao and N. Aotsuka and H. Sawada and K. Shinagawa and M. Kasai and T. Iseki and M. Murata and S. Okamoto and H. Hyodo and Y. Kodera",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "40",
pages = "1160--1167",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "11",

}

TY - JOUR

T1 - Nationwide survey of allogeneic peripheral blood stem cell transplantation from related donors in Japan

T2 - current trends and issues

AU - Harada, M.

AU - Takenaka, Katsuto

AU - Nakao, S.

AU - Aotsuka, N.

AU - Sawada, H.

AU - Shinagawa, K.

AU - Kasai, M.

AU - Iseki, T.

AU - Murata, M.

AU - Okamoto, S.

AU - Hyodo, H.

AU - Kodera, Y.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - In December 1997, we conducted a nationwide survey of cases of primary allogeneic peripheral blood stem cell transplantation (allo-PBSCT) performed in Japan between December 1994 and November 1997 Data was collected on 103 patients with hematologic malignancies, aplastic anemia, or solid tumors. Eighty-seven patients received transplants from HLA-identical siblings, and 16 from HLA-mismatched related donors. Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) were collected from donors by 1 to 3 aphereses. Apheresis products contained a median 5.4 (1.0-30.4) x 10(6) CD34 + cells/kg. Most patients were given cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Median days to ANC > 500/microliter and platelets > 50,000/microliter were 13 (7-49) and 16 (10-94), respectively. Grade II-IV acute GVHD developed in 37/99 (37.4%) and chronic GVHD in 59/86 (68.6%) patients. The incidence of treatment-related mortality within 100 days after transplant was 16.1%. Fifty-five patients (59.6%) were alive after a median follow-up of 794 days. More patients and longer follow-up periods will be required to assess the efficacy of allo-PBSCT and evaluate graft-versus-leukemia effect along with the incidence of acute and chronic GVHD.

AB - In December 1997, we conducted a nationwide survey of cases of primary allogeneic peripheral blood stem cell transplantation (allo-PBSCT) performed in Japan between December 1994 and November 1997 Data was collected on 103 patients with hematologic malignancies, aplastic anemia, or solid tumors. Eighty-seven patients received transplants from HLA-identical siblings, and 16 from HLA-mismatched related donors. Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) were collected from donors by 1 to 3 aphereses. Apheresis products contained a median 5.4 (1.0-30.4) x 10(6) CD34 + cells/kg. Most patients were given cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Median days to ANC > 500/microliter and platelets > 50,000/microliter were 13 (7-49) and 16 (10-94), respectively. Grade II-IV acute GVHD developed in 37/99 (37.4%) and chronic GVHD in 59/86 (68.6%) patients. The incidence of treatment-related mortality within 100 days after transplant was 16.1%. Fifty-five patients (59.6%) were alive after a median follow-up of 794 days. More patients and longer follow-up periods will be required to assess the efficacy of allo-PBSCT and evaluate graft-versus-leukemia effect along with the incidence of acute and chronic GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0033220120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033220120&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 1160

EP - 1167

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 11

ER -